ScoreWhy is Piramal Pharma Ltd ?
1
Weak Long Term Fundamental Strength with a -9.27% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 6.16 times
- The company has been able to generate a Return on Equity (avg) of 0.58% signifying low profitability per unit of shareholders funds
2
Negative results in Jun 26
- PBT LESS OI(Q) At Rs -96.87 cr has Fallen at -100.5% (vs previous 4Q average)
- ROCE(HY) Lowest at 2.61%
- DEBT-EQUITY RATIO(HY) Highest at 0.70 times
3
With ROCE of 0.7, it has a Expensive valuation with a 2.6 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 9.20%, its profits have fallen by -225.1%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Piramal Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Piramal Pharma
9.2%
0.27
33.85%
Sensex
-2.63%
-0.19
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.14%
EBIT Growth (5y)
-9.27%
EBIT to Interest (avg)
0.82
Debt to EBITDA (avg)
5.22
Net Debt to Equity (avg)
0.53
Sales to Capital Employed (avg)
0.64
Tax Ratio
100.00%
Dividend Payout Ratio
20.35%
Pledged Shares
0
Institutional Holding
27.09%
ROCE (avg)
2.41%
ROE (avg)
0.58%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
37
Price to Book Value
3.39
EV to EBIT
209.66
EV to EBITDA
31.68
EV to Capital Employed
2.56
EV to Sales
3.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.72%
ROE (Latest)
-1.59%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-9What is not working for the Company
PBT LESS OI(Q)
At Rs -96.87 cr has Fallen at -100.5% (vs previous 4Q average
ROCE(HY)
Lowest at 2.61%
DEBT-EQUITY RATIO(HY)
Highest at 0.70 times
Loading Valuation Snapshot...
Here's what is not working for Piramal Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -96.87 cr has Fallen at -100.5% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs -48.31 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Debt-Equity Ratio - Half Yearly
Highest at 0.70 times
in the last five half yearly periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income - Quarterly
Highest at Rs 89.41 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
